News from micell technologies A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

23 May, 2018, 19:18 BST Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this...


06 Dec, 2017, 17:58 GMT The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®

Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint,...


16 May, 2017, 12:23 BST Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Micell Technologies announced today at the late-breaking trial session of EuroPCR – the official congress of the European Association of Percutaneous ...


31 Oct, 2016, 15:00 GMT Positive Five-Year Clinical Data from Micell Technologies' MiStent Presented at TCT 2016

Micell Technologies, Inc. (Micell) today announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials ...


13 Oct, 2015, 13:00 BST Positive Four-Year Clinical Data from Micell Technologies' MiStent SES Presented at TCT 2015

Micell Technologies, Inc. today announced four-year clinical results from the DESSOLVE I and II trials of its MiStent Sirolimus Eluting Absorbable...


20 Aug, 2015, 13:00 BST Micell Technologies Announces Surgical Technologies Approved as MiStent SES Commercial Manufacturer for CE Mark Countries

Micell Technologies, Inc. announced that its application for a manufacturing partner, Surgical Technologies, Inc. (STI), was approved by British...


19 May, 2015, 13:00 BST EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment

At the late-breaking trials session today at EuroPCR, the official congress of European Association of Percutaneous Cardiovascular Interventions,...


28 Oct, 2013, 12:00 GMT MiStent SES Shown to be Unique in Clinical Setting

Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus...


09 Oct, 2013, 08:00 BST Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China

Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life...


08 Oct, 2013, 08:00 BST Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiology's Cardiovascular Interventions Journal

Micell Technologies, Inc. today announced that a peer reviewed article discussing imaging and clinical results of the DESSOLVE I trial of its MiStent ...